Evidence map›Paper›PMID 37716347›Full record

ArticleCell chemical biology2023

Metabolic modulation of mitochondrial mass during CD4

Kiran Kurmi, Dan Liang, Robert van de Ven, Peter Georgiev, Brandon Mark Gassaway, SeongJun Han, Giulia Notarangelo, Isaac S Harris, Cong-Hui Yao, Joon Seok Park and 10 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell chemical biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Mitochondrial response to fever boosts TImmunometabolism (Cobham, Surrey) · 2025
    Article
  4. Article
  5. Article
  6. Review
  7. Peripheral CX3CR1Oncoimmunology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 1 institution in 1 country.

Kiran KurmiDepartment of Cell Biology, Blavatnik Institute Harvard Medical School, Boston, MA 02115, USA.
Dan LiangDepartment of Immunology, Blavatnik Institute Harvard Medical School, Boston, MA 02115, USA.
Robert van de VenDepartment of Cell Biology, Blavatnik Institute Harvard Medical School, Boston, MA 02115, USA.
Peter GeorgievDepartment of Cell Biology, Blavatnik Institute Harvard Medical School, Boston, MA 02115, USA; Department of Immunology, Blavatnik Institute Harvard Medical School, Boston, MA 02115, USA.
Brandon Mark GassawayDepartment of Cell Biology, Blavatnik Institute Harvard Medical School, Boston, MA 02115, USA.
SeongJun HanDepartment of Cell Biology, Blavatnik Institute Harvard Medical School, Boston, MA 02115, USA; Department of Immunology, Blavatnik Institute Harvard Medical School, Boston, MA 02115, USA.
Giulia NotarangeloDepartment of Cell Biology, Blavatnik Institute Harvard Medical School, Boston, MA 02115, USA.
Isaac S HarrisDepartment of Cell Biology, Blavatnik Institute Harvard Medical School, Boston, MA 02115, USA.
Cong-Hui YaoDepartment of Cell Biology, Blavatnik Institute Harvard Medical School, Boston, MA 02115, USA.
Joon Seok ParkDepartment of Immunology, Blavatnik Institute Harvard Medical School, Boston, MA 02115, USA.
Song-Hua HuDepartment of Cell Biology, Blavatnik Institute Harvard Medical School, Boston, MA 02115, USA.
Jingyu PengDepartment of Cell Biology, Blavatnik Institute Harvard Medical School, Boston, MA 02115, USA.
Jefte M DrijversDepartment of Cell Biology, Blavatnik Institute Harvard Medical School, Boston, MA 02115, USA; Department of Immunology, Blavatnik Institute Harvard Medical School, Boston, MA 02115, USA.
Sarah BoswellLaboratory of Systems Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
Artem SokolovLaboratory of Systems Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
Stephanie K DouganDepartment of Immunology, Blavatnik Institute Harvard Medical School, Boston, MA 02115, USA; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Peter K SorgerLaboratory of Systems Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
Steven P GygiDepartment of Cell Biology, Blavatnik Institute Harvard Medical School, Boston, MA 02115, USA.
Arlene H SharpeDepartment of Immunology, Blavatnik Institute Harvard Medical School, Boston, MA 02115, USA.
Marcia C HaigisDepartment of Cell Biology, Blavatnik Institute Harvard Medical School, Boston, MA 02115, USA. Electronic address: marcia_haigis@hms.harvard.edu.
Harvard University · US

Funding

Systems Pharmacology of Therapeutic and Adverse Responses to ImmuneCheckpoint and Small Molecule DrugsU54CA225088 · NCI · HARVARD MEDICAL SCHOOL · PI HAIGIS, MARCIA · 2018 to 2022
$10.8M
New Sample Multiplexing Technologies to Identify Chemical Probes and Illuminate Ubiquitin BiologyR01GM067945 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI GYGI, STEVEN P · 2003 to 2024
$10.5M
Defining mechanisms to promote antitumor immunity by modulating one-carbon metabolismR01CA276866 · NCI · HARVARD MEDICAL SCHOOL · PI MARCIA HAIGIS, Arlene H. Sharpe · 2023 to 2026
$2.2M
CDK4/6 inhibition during CD8 T cell priming potentiates memory formation in mice and humansR01AI158488 · NIAID · DANA-FARBER CANCER INST · PI DOUGAN, STEPHANIE · 2021 to 2025
$2.2M
Impact of extracellular glutathione catabolism on triple-negative breast cancerR01CA269813 · NCI · UNIVERSITY OF ROCHESTER · PI Jeevisha Bajaj · 2022 to 2026
$2.2M
Molecular mechanisms of Nutrient sensing in cancerR01CA213062 · NCI · HARVARD MEDICAL SCHOOL · PI HAIGIS, MARCIA · 2017 to 2021
$1.9M
Investigating the role of PHD3 in lipid homeostasisR01DK127278 · NIDDK · HARVARD MEDICAL SCHOOL · PI HAIGIS, MARCIA · 2021 to 2024
$1.7M
Role of the Gut Microbiota in Regulating Responses to anti-PD-1 Cancer ImmunotherapyF32CA247072 · NCI · HARVARD MEDICAL SCHOOL · PI PARK, JOON SEOK · 2020 to 2022
$212k
Metabolic regulation of anti-tumor T cell responsesF31CA224601 · NCI · HARVARD MEDICAL SCHOOL · PI DRIJVERS, JEFTE M. · 2018 to 2020
$98k
NCI NIH HHS F31 CA224601NCI NIH HHS F32 CA247072NCI NIH HHS R01 CA213062NCI NIH HHS R01 CA269813NCI NIH HHS R01 CA276866NCI NIH HHS U54 CA225088NIAID NIH HHS R01 AI158488NIDDK NIH HHS R01 DK127278NIGMS NIH HHS R01 GM067945
6 · The paper itself

Abstract

Mitochondrial biogenesis initiates within hours of T cell receptor (TCR) engagement and is critical for T cell activation, function, and survival; yet, how metabolic programs support mitochondrial biogenesis during TCR signaling is not fully understood. Here, we performed a multiplexed metabolic chemical screen in CD4

Indexed as

Encephalomyelitis, Autoimmune, ExperimentalAnimalsCD4-Positive T-LymphocytesLymphocyte ActivationMiceReceptors, Antigen, T-CellT-LymphocytesReceptors, Antigen, T-CellCD4(+) T cellshigh-throughput metabolic screenmitochondrial biogenesispyruvate oxidationpyrvinium pamoateT cell differentiation

Identifiers

PMID37716347
PMCPMC10604707
OpenAlexW4386769307

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.